Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542026 | 0.95 | KDM4E (0.65) | KDM4EGAADRD2DRD3SIGMAR1 | |
| SCHEMBL5542882 | 0.93 | KDM4E (0.68) | KDM4EGAADRD2DRD3SIGMAR1 | |
| SCHEMBL4576289 | 0.89 | DRD2 (0.68) | KDM4EGAADRD2DRD3SIGMAR1 | |
| SCHEMBL155128 | 0.82 | SIGMAR1 (0.79) | KDM4EGAADRD2DRD3SIGMAR1 | |
| SCHEMBL4576516 | 0.82 | DRD2 (0.46) | KDM4EGAADRD2DRD3SIGMAR1 | |
| SCHEMBL188197 | 0.82 | CHRNA7 (0.66) | KDM4EGAADRD2SIGMAR1DRD4 | |
| SCHEMBL10724890 | 0.79 | GAA (0.62) | KDM4EGAADRD2DRD3SIGMAR1 | |
| SCHEMBL14459608 | 0.79 | KDM4E (0.88) | KDM4EGAADRD2DRD3SIGMAR1 | |
| SCHEMBL29258877 | 0.79 | KDM4E (0.69) | KDM4EGAADRD2DRD3SIGMAR1 | |
| SCHEMBL8223307 | 0.79 | KDM4E (0.62) | KDM4EGAADRD2DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103087122-A | Preparation method and applications of glucoside compounds | SHANGHAI INST ORGANIC CHEM | 2013-05-08 | — | — | CN | claimed |
| CN-103087122-A | Preparation method and applications of glucoside compounds | SHANGHAI INST ORGANIC CHEM | 2013-05-08 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | KDM4E 4854/4885GAA 4165/4885DRD2 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.